Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the importance of utilizing next-generation sequencing (NGS) to identify optimal therapies for lung cancer patients. Dr Johnson describes how the addition of immunotherapy to chemotherapy does not benefit all lung cancer patients equally, with patients with low or no expression of PDL1 having significantly reduced or no additional benefit. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).